Search Results for "sulfacetamide"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for sulfacetamide. Results 1 to 2 of 2 total matches.

Roflumilast Foam (Zoryve) for Seborrheic Dermatitis

   
The Medical Letter on Drugs and Therapeutics • Apr 15, 2024  (Issue 1700)
Drug Some Formulations Usual Adult Dosage2 Cost/Size3 Antibacterial Sulfacetamide – generic 10 ...
The FDA has approved a 0.3% foam formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of seborrheic dermatitis in patients ≥9 years old. Roflumilast is the first PDE4 inhibitor to be approved in the US for this indication. It is also available in a 0.3% cream formulation (Zoryve) for treatment of plaque psoriasis and in an oral formulation (Daliresp, and generics) for treatment of chronic obstructive pulmonary disease. A 0.15% cream formulation for treatment of atopic dermatitis in patients ≥6 years old will be reviewed...
Med Lett Drugs Ther. 2024 Apr 15;66(1700):57-9   doi:10.58347/tml.2024.1700a |  Show IntroductionHide Introduction

Drugs for Rosacea

   
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024  (Issue 1695)
acid.3,4 Topical erythromycin, clindamycin, and sulfacetamide/sulfur have also been used.1 IVERMECTIN ...
Rosacea is a common, chronic inflammatory facial eruption of unknown cause. It is more prevalent in women than in men, and disease onset typically occurs after age 30. Rosacea is characterized by erythema, telangiectasia, and flushing, and sometimes by recurrent, progressive crops of acneiform papules and pustules, usually on the central part of the face. Some patients develop granulomas and tissue hypertrophy, which may lead to rhinophyma (a bulbous nose), particularly in men. Blepharitis and conjunctivitis are common. Keratitis and corneal scarring occur rarely.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):21-2   doi:10.58347/tml.2024.1695b |  Show IntroductionHide Introduction